A woman smiles, sitting in a dark stained wooden chair with gold accents, wearing a large medal, while another woman applauds in the background.

U-M’s Zhen Xu, histotripsy co-inventor, honored with endowed professorship from Li Ka Shing Foundation

Foundation looks to support histotripsy research at the place it was invented.

Experts

Zhen Xu

Portrait of Zhen Xu

See full bio

Li Ka Shing Endowed Professor of Biomedical Engineering

Zhen Xu, a University of Michigan pioneer in developing the tumor-destroying histotripsy treatment, will expand her partnership with the Hong Kong-based Li Ka Shing Foundation (LKSF) through a new $2.5 million endowed professorship.

It’s a partnership designed to be the means to an end—of cancer.

On Friday, Xu was honored with a Li Ka Shing Endowed Professorship of Biomedical Engineering at U-M. Foundation leaders want to continue and deepen their support of histotripsy at the place where it was invented. A ceremony was held to mark the occasion at the Gerald R. Ford Presidential Library.

Endowed professorships are funded by donors and provide additional resources to acknowledge outstanding research, teaching and service. They are among the highest honors Michigan Engineering can award a faculty member. Mr. Li Ka-shing, a famed philanthropist, and Solina Chau, the foundation’s director, met with Xu, a U-M professor of biomedical engineering, in Hong Kong as a new histotripsy device was delivered to a local hospital.

A woman speaks from a podium. The slide reads "Born and Grown Up in Nanjing, China. Mama and Baba: Respect for every human being, Being honest, Being grateful to all kindness and support."

A family photo features Huifen Zhang (mother), Naihu Xu (father), and Little Zhen.
U-M’s Zhen Xu, the newly-named Li Ka Shing Endowed Professor of Biomedical Engineering and a co-inventor of histotripsy, discusses the early influence of her parents on her professional journey toward becoming a co-inventor of histotripsy. Photo: Brenda Ahearn, Michigan Engineering

“When we shared the potential of this precise, targeted, effective and painless option for combating cancer with Mr. Li Ka-Shing, his response was straightforward and resolute,” Chau said. “He said ‘This is truly incredible. We should support its research and treatment services wherever possible, and please expedite it.’”

Zhen Xu stands with two women on a stage with a screen that displays "a decade in innovation: the next chapter" for the UBS Disruptive Technology CEO Summit 2024, hosted in Hong Kong.
Zhen Xu (middle) discussed histotripsy and HistoSonics, Inc. with Ms. Solina Chau (left), the Li Ka Shing Foundation’s director, at the UBS Disruptive Technology CEO Summit 2024 organized by Amy Lo, JP (right), , UBS Global Wealth Management, Head and Chief Executive, on November 20th, 2024 in Hong Kong.

Histotripsy uses precisely-targeted ultrasound pulses to break down targeted tissues such as tumors, leaving miniscule harmless debris that can be absorbed by the body. It’s an alternative treatment for cancers that comes without the risks of surgery and the taxing side effects of chemotherapy and radiation.

Years of research collaboration between Michigan Engineering and Michigan Medicine have helped push histotripsy out of the lab and into the mainstream. The technology is currently being used to treat patients with liver tumors, and human trials are now underway for patients with kidney and pancreatic tumors.

Histotripsy has been commercialized by U-M startup HistoSonics, co-founded by Xu and a group of university engineers and doctors in 2009. And histrotripsy’s potential has amassed an ever-growing group of supporters.

A woman stands among the applauding audience members, with a smile and wave.
Solina Chau, director of the Li Ka Shing Foundation, acknowledges the audience at the Gerald R. Ford Presidential Library during a ceremony recognizing a new endowed professorship for U-M’s Zhen Xu, a co-inventor of the tumor treatment histotripsy. Photo: Brenda Ahearn, Michigan Engineering

“This has been an amazing journey so far, and it’s the result of the work of so many people,” Xu said. “There have been nearly a hundred people here at U-M that we’ve worked with directly or indirectly, and HistoSonics now employs almost 200 people. And now we have people like Mr. Li Ka-Shing and Ms. Solina Chau supporting us along with other donors.

“I used to tell people it takes a village, but that’s not enough. It takes an army.”

Li Ka-shing, Chau and the foundation are no strangers to U-M, having now given nearly $10 million to projects at the College of Engineering and Michigan Medicine. Those include:

In the coming months, LKSF officials are looking to expand their current relationship with Michigan Medicine as well. The foundation plans a $4 million donation that will fund a new endowed research professorship and new research in liver cancer diagnosis, treatment and prevention.

Digital rendering of the the Edison Histotripsy System that was developed by HistoSonics, a startup company founded by U-M engineers and doctors in 2009. The image displays a robotic surgical system over a digital patient with a medical imaging display.
The Edison Histotripsy System was developed by HistoSonics, a startup company founded by U-M engineers and doctors in 2009.

“We extend our deepest gratitude to the Li Ka Shing Foundation for their steadfast support of our programs,” said Karen A. Thole, the Robert J. Vlasic Dean of Engineering and a professor of mechanical engineering and aerospace engineering. “Together, through this invaluable partnership, we are turning the promise of transforming the lives of patients and their families around the globe into a tangible reality.”

Xu’s journey toward histotripsy began as she worked toward her master’s (2003) and doctorate (2005) degrees at U-M in biomedical engineering. She worked with the late Charles Cain (PhD EE ’72), a distinguished BME professor and a founder of the U-M Biomedical Engineering Department.

Cain devoted much of his career attempting to use soundwaves as a “knife-less surgical approach” for treating all manner of maladies. Xu’s work in the lab helped make that vision a reality.

The result can be seen in HistoSonics’ Edison Histotripsy System

A woman smiles, sitting in a dark stained wooden chair with gold accents, wearing a large medal, while another woman applauds in the background.
U-M’s Zhen Xu (right), the newly-named Li Ka Shing Endowed Professor of Biomedical Engineering and a co-inventor of histotripsy, tries out the ceremonial chair that comes with her new title. Karen Thole, the Robert J. Vlasic Dean of Engineering, leads the applause. Photo: Brenda Ahearn, Michigan Engineering.

“It’s taken over 20 years to realize histotripsy’s potential in routine clinical care and it’s humbling to represent a technology that is changing the paradigm in cancer care and likely human health on a larger scale,” said Mike Blue, HistoSonics’ CEO and president. “Demand from patients, physician users, and hospital systems across the country is a testament to the magnitude of Zhen’s invention. 

“In addition, the recognition of histotripsy’s profound importance from the Li Ka Shing Foundation has accelerated adoption and access to patients in need across the globe, for which we are very grateful.”

Late in 2024, Xu was named a fellow of the National Academy of Inventors and a fellow of the Institute of Electrical and Electronics Engineers. In November, she travelled to Hong Kong for the Li Ka Shing Foundation’s donation of an Edison Histotripsy System to the Chinese University of Hong Kong.

“Professor Xu’s visionary work in the field of histotripsy has been truly groundbreaking and BME is extremely proud of her achievements,” said Mary-Ann Mycek, the William and Valerie Hall department chair and a professor of biomedical engineering. “We’re grateful to the Li Ka Shing Foundation for its ongoing commitment to our department and the generous support it has provided over the years.

“The endowed professorship reflects both the excellence and impact of Professor Xu’s research, as well as the potential of histotripsy to significantly improve patients’ lives worldwide.”

“The endowed professorship reflects both the excellence and impact of Professor Xu’s research, as well as the potential of histotripsy to significantly improve patients’ lives worldwide.”

Mary-Ann Mycek, the William and Valerie Hall department chair and a professor of biomedical engineering.

Uniquely positioned as a joint department in both the College of Engineering and the Medical School, U-M’s Biomedical Engineering department is a leader in education, research and clinical translation. U-M BME has one of the oldest and largest biomedical engineering departments in the country.